Code Sets

email_03Get Email Updates

To receive email updates about this page, enter your email address:

For more information on background and concepts see Understanding the Rules for Creating CVX and MVX Codes pdf icon[5 pages]

Preview Posting of COVID-19 Vaccine Codes and Crosswalk in Anticipation of Potential Vaccine Availability under Emergency Use Authorization (EUA)

Note: Codes will become effective only upon EUA issuance of COVID-19 vaccine(s) by the Food and Drug Administration (FDA)

The codes and crosswalk for candidate COVID-19 vaccines will be posted for preview in phases as the late-stage clinical trials for candidate vaccines progress. Additional vaccines will be added to this list as they enter late-stage clinical trials.

The following downloadable table provides a preview of the vaccine codes that will be activated if the FDA authorizes use and ACIP votes to recommend the candidate vaccines currently being studied in clinical trials.

To support this effort, the CDC is working closely with data partners responsible for the creation and distribution of vaccine codes and drug compendia publishers to coordinate the release of codes in advance of potential EUAs to enable systems and users that require these codes to prepare in advance.

The codes for these vaccines are also included in the vaccine code set files.

American Medical Association (AMA) COVID-19 CPT® vaccine product and administration codes are now available on the AMA web site.  The CPT vaccine product codes are included in the Preview COVID-19 table and the CDC vaccine code sets.  You can access further information regarding the COVID-19 CPT codes, as well as the associated coding guidance, using the following link:

https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codesexternal icon

Download the Preview Table: Preview COVID-19 Vaccine Codes Potential EUA 20201231excel icon

Preview Posting of COVID-19 Vaccine Codes and Crosswalk. Provided in anticipation of potential vaccine availability under Emergency Use Authorization (EUA) Data as of 12/31/2020. Codes will become effective only upon EUA issuance of COVID-19 vaccine(s) by the Food and Drug Administration (FDA). All CVX Codes are associated to the new Vaccine Group “COVID-19”
CVX Code CVX Long Description CVX Short Description Sale Proprietary Name Sale Labeler MVX Code Unit of Sale NDC10 (UOS) UoS Package Unit of Use NDC10 (UOU) Presentation CPT Code CPT Description
207 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose COVID-19, mRNA, LNP-S, PF, 100 mcg/ 0.5 mL dose Moderna COVID-19 Vaccine Moderna US, Inc. MOD 80777-273-99 CARTON, 10 MULTI-DOSE VIALS 80777-273-10 MULTI-DOSE VIAL, 10 DOSES 91301 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use
208 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose Pfizer COVID-19 Vaccine Pfizer-BioNtech PFR 59267-1000-2 CARTON, 195 MULTI-DOSE VIALS 59267-1000-1 MULTI-DOSE VIAL 91300 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use
208 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose Pfizer COVID-19 Vaccine Pfizer-BioNTech PFR 59267-1000-3 CARTON, 25 MULTI-DOSE VIALS 59267-1000-1 MULTI-DOSE VIAL 91300 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use
210 SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL AstraZeneca COVID-19 Vaccine AstraZeneca Pharmaceuticals LP ASZ 0310-1222-15 CARTON, 10 MULTI-DOSE VIALS 0310-1222-10 MULTI-DOSE VIAL, 10 DOSES 91302 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5×1010 viral particles/0.5mL dosage, for intramuscular use

Preview Posting of Codes for Emergency Use Authorization (EUA) Fact Sheets for Recipients and Caregivers

Vaccine information statements (VISs), used only for licensed vaccines, will not be available for COVID-19 vaccines while they are under Emergency Use Authorization (EUA). For vaccines under an EUA, the FDA requires a vaccine-specific Fact Sheet for Recipients and Caregivers be provided to vaccine recipients or their caregivers.

The COVID-19 vaccine-related codes are provided in anticipation of potential vaccine availability under an EUA. If a vaccine is not authorized, the code will be retired.

The FDA issued Emergency Use Authorization for the Moderna COVID-19 vaccine on Friday December 18, 2020.  Information regarding that vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:

https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccineexternal icon

The FDA issued Emergency Use Authorization for the Pfizer BioNTech COVID-19 vaccine on Friday December 11, 2020.  Information regarding that vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:

https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccineexternal icon

The following downloadable VIS code files will include the new EUA Fact Sheet for Recipients records:

Preview Posting of Codes for Emergency Use Authorization (EUA) Fact Sheets for Recipients and Caregivers”
CVX Code EUA Recipient/Caregiver Fact Sheet Description Document Barcode String Edition Date Edition Status HTML URL PDF URL VIS GDTI document code
207 COVID-19 Moderna Vaccine EUA Recipient-Caregiver Fact Sheet 253088698300034911201201 12/01/2020 Current https://www.cdc.gov/vaccines/covid-19/eua/modernatx.html https://www.cdc.gov/vaccines/covid-19/eua/modernatx.pdfpdf icon 0886983000349
208 COVID-19 Pfizer BioNTech Vaccine EUA Recipient-Caregiver Fact Sheet 253088698300033211201201 12/01/2020 Current https://www.cdc.gov/vaccines/covid-19/eua/pfizer.html https://www.cdc.gov/vaccines/covid-19/eua/pfizer.pdfpdf icon 0886983000332

*Edition date is the date of the barcode generated-edition date and does not reflect the exact date that the EUA Fact Sheet was issued.

2020/2021 Seasonal Influenza Codes and Crosswalk

This new format includes all seasonal influenza vaccines for the 2020/2021 season in a single Excel crosswalk table that provides the CVX, MVX, NDC Unit of Sale, NDC Unit of Use, and CPT (*)  codes for each vaccine.

(*) Please note that the CPT codes shown for each vaccine crosswalk are not mapped to the NDC codes, but are mapped to the CVX codes shown.  These are reference CPT codes for vaccine categorization and are not intended to represent billable codes.

Download the Seasonal Influenza Crosswalk tableexcel icon

Influenza Vaccines for Season 2020/2021 (Northern Hemisphere)
CVX Code CVX Short Description Sale Proprietary Name Sale Labeler MVX Code Unit of Sale NDC11 Unit of Use NDC11 Presentation CPT Code CPT Description
149 influenza, live, intranasal, quadrivalent FluMist Quadrivalent MedImmune, LLC MED 66019-0307-10 66019-0307-01 APPLICATOR .2 mL 90672 Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use
150 influenza, injectable, quadrivalent, preservative free Flulaval Quadrivalent ID Biomedical Corporation of Quebec IDB 19515-0816-52 19515-0816-41 SYRINGE, .5 mL 90686 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use
150 influenza, injectable, quadrivalent, preservative free Afluria Quadrivalent Seqirus Pty Ltd. SEQ 33332-0320-01 33332-0320-02 SYRINGE, .5 mL 90686 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use
150 influenza, injectable, quadrivalent, preservative free FLUZONE QUADRIVALENT Sanofi Pasteur Inc. PMC 49281-0420-10 49281-0420-58 VIAL, .5 mL, SINGLE-DOSE 90686 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use
150 influenza, injectable, quadrivalent, preservative free FLUZONE QUADRIVALENT Sanofi Pasteur Inc. PMC 49281-0420-50 49281-0420-88 SYRINGE, .5 mL 90686 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use
150 influenza, injectable, quadrivalent, preservative free FLUARIX QUADRIVALENT GlaxoSmithKline Biologicals SA SKB 58160-0885-52 58160-0885-41 SYRINGE, .5 mL 90686 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use
158 influenza, injectable, quadrivalent Afluria Quadrivalent Seqirus Pty Ltd. SEQ 33332-0420-10 33332-0420-11 VIAL, 5 mL, MULTI-DOSE 90687 Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use
90688 Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use
158 influenza, injectable, quadrivalent FLUZONE QUADRIVALENT Sanofi Pasteur Inc. PMC 49281-0633-15 49281-0633-78 VIAL, 5 mL, MULTI-DOSE 90687 Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use
90688 Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use
161 Influenza, injectable,quadrivalent, preservative free, pediatric Afluria Quadrivalent Seqirus Pty Ltd. SEQ 33332-0220-20 33332-0220-21 SYRINGE, .25 mL 90685 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use
161 Influenza, injectable,quadrivalent, preservative free, pediatric FLUZONE QUADRIVALENT Sanofi Pasteur Inc. PMC 49281-0520-25 49281-0520-00 SYRINGE, .25 mL 90685 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use
168 influenza, trivalent, adjuvanted FLUAD Seqirus, Inc. SEQ 70461-0020-03 70461-0020-04 SYRINGE, .5 mL 90653 Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use
171 Influenza, injectable, MDCK, preservative free, quadrivalent FLUCELVAX QUADRIVALENT Seqirus Inc. SEQ 70461-0320-03 70461-0320-04 SYRINGE, .5 mL 90674 Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use
185 influenza, recombinant, quadrivalent,injectable, preservative free Flublok Quadrivalent Northern Hemisphere Sanofi Pasteur Inc. PMC 49281-0720-10 49281-0720-88 SYRINGE, .5 mL 90682 Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use
186 Influenza, injectable, MDCK, quadrivalent, preservative FLUCELVAX QUADRIVALENT Seqirus Inc. SEQ 70461-0420-10 70461-0420-11 VIAL, 5 mL, MULTI-DOSE 90756 Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use
197 influenza, high-dose, quadrivalent FLUZONE High-Dose Quadrivalent Northern Hemisphere Sanofi Pasteur Inc. PMC 49281-0120-65 49281-0120-88 SYRINGE, .7 mL 90662 Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use
205 Influenza vaccine, quadrivalent, adjuvanted FLUAD QUADRIVALENT Seqirus, Inc. SEQ 70461-0120-03 70461-0120-04 SYRINGE, .5 mL 90694 Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use
Southern Hemisphere 2020 Influenza Season
CVX Code CVX Short Description Sale Proprietary Name Sale Labeler MVX Code Unit of Sale NDC11 Unit of Use NDC11 Presentation
200 influenza, Southern Hemisphere, pediatric, preservative free FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE Sanofi Pasteur Inc. PMC 49281-0181-25 49281-0181-00 Syringe, glass, .25 mL
201 influenza, Southern Hemisphere, preservative free FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE Sanofi Pasteur Inc. PMC 49281-0320-50 49281-0320-88 Syringe, glass, .5 mL
202 influenza, Southern Hemisphere, quadrivalent, with preservative FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE Sanofi Pasteur Inc. PMC 49281-0336-15 49281-0336-78 Vial, 5 mL, MULTI-DOSE
Page last reviewed: June 7, 2019